Table of Content

Chapter 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
1.4.4.Primary research

Chapter 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

Chapter 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key Findings

3.2.1.Top investment pockets
3.2.2.Top winning strategies

3.3.Top player positioning
3.4.Porter’s five force analysis
3.5.Government Regulations
3.6.Market dynamics

3.6.1.Drivers

3.6.1.1.Rise in incidences of chronic diseases
3.6.1.2.Favorable regulatory scenario
3.6.1.3.Increase in geriatric population

3.6.2.Restraints

3.6.2.1.Availability of alternative therapies
3.6.2.2.Drug Exploitation
3.6.2.3.Patent expiration of prescription drugs

3.6.3.Opportunities

3.6.3.1.Advancements in drug development
3.6.3.2.Untapped markets in developing economies

3.7.COVID-19 Impact Analysis for Pain Management Drugs

Chapter 4:GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS

4.1.Overview

4.1.1.Market size and forecast

4.2.NSAIDS

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country

4.3.Anesthetics

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country

4.4.Anticonvulsant

4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country

4.5.Antimigraine Drug

4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country

4.6.Antidepressant drugs

4.6.1.Key market trends, growth factors, and opportunities
4.6.2.Market size and forecast, by region
4.6.3.Market analysis, by country

4.7.Opioids

4.7.1.Key market trends, growth factors, and opportunities
4.7.2.Market size and forecast, by region
4.7.3.Market analysis, by country
4.7.4.Tramadol
4.7.5.Hydrocodone
4.7.6.Oxycodone
4.7.7.Others

4.8.Non-narcotic analgesics

4.8.1.Key market trends, growth factors, and opportunities
4.8.2.Market size and forecast, by region
4.8.3.Market analysis, by country

Chapter 5:GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY INDICATION

5.1.Overview

5.1.1.Market size and forecast

5.2.Arthritic Pain

5.2.1.Market size and forecast, by region
5.2.1.Market analysis, by country

5.3.Neuropathic pain

5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country

5.4.Cancer Pain

5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country

5.5.Chronic Pain

5.5.1.Market size and forecast, by region
5.5.2.Market analysis, by country

5.6.Post-operative pain

5.6.1.Market size and forecast, by region
5.6.2.Market analysis, by country

5.7.Migraine

5.7.1.Market size and forecast, by region
5.7.2.Market analysis, by country

5.8.Fibromyalgia

5.8.1.Market size and forecast, by region
5.8.2.Market analysis, by country

Chapter 6:PAIN MANAGEMENT DRUGS MARKET, BY REGION

6.1.Overview

6.1.1.Market size and forecast

6.2.North America

6.2.1.Key market trends, growth factors, and opportunities
6.2.2.North America Pain Management Drugs Market, by country

6.2.2.1.U.S. Pain Management Drugs Market, by drug class
6.2.2.2.U.S Pain Management Drugs Market, by indications
6.2.2.3.Canada Pain Management Drugs Market, by drug class
6.2.2.4.Canada Pain Management Drugs Market, by indication
6.2.2.5.Mexico Pain Management Drugs Market, by product
6.2.2.6.Mexico Pain Management Drugs Market, by indication

6.2.3.North America Pain Management Drugs Market, by drug class
6.2.4.North America Pain Management Drugs Market, by indication

6.3.Europe

6.3.1.Key market trends, growth factors, and opportunities
6.3.2.Europe Pain Management Drugs Market, by country

6.3.2.1.UK Pain Management Drugs Market, by drug class
6.3.2.2.UK Pain Management Drugs Market, by indication
6.3.2.3.Germany Pain Management Drugs Market, by drug class
6.3.2.4.Germany Pain Management Drugs Market, by indication
6.3.2.5.France Pain Management Drugs Market, by drug class
6.3.2.6.France Pain Management Drugs Market, by indication
6.3.2.7.Italy Pain Management Drugs Market, by drug class
6.3.2.8.Italy Pain Management Drugs Market, by indication
6.3.2.9.Spain Pain Management Drugs Market, by drug class
6.3.2.10.Spain Pain Management Drugs Market, by indication
6.3.2.11.Rest of Europe Pain Management Drugs Market, by drug class
6.3.2.12.Rest of Europe Pain Management Drugs Market, by indication

6.3.3.Europe Pain Management Drugs Market, by drug Class
6.3.4.Europe Pain Management Drugs Market, by indication

6.4.Asia Pacific
6.5.Key market trends, growth factors, and opportunities

6.5.1.Asia-Pacific Pain Management Drugs Market, by country

6.5.1.1.Japan pain management drugs market, by drug class
6.5.1.2.Japan pain management drugs market, by indications
6.5.1.3.China pain management drugs market, by drug class
6.5.1.4.China Pain Management Drugs Market, by indication
6.5.1.5.Australia Pain Management Drugs Market, by drug class
6.5.1.6.Australia Pain Management Drugs Market, by indication
6.5.1.7.India Pain Management Drugs Market, by drug class
6.5.1.8.India Pain Management Drugs Market, by indication
6.5.1.9.South Korea Pain Management Drugs Market, by drug class
6.5.1.10.South Korea Pain Management Drugs Market, by indication
6.5.1.11.Taiwan Pain Management Drugs Market, by drug class
6.5.1.12.Taiwan Pain Management Drugs Market, by indication
6.5.1.13.Rest of Asia-Pacific Pain Management Drugs Market, by drug class
6.5.1.14.Rest of Asia-Pacific Pain Management Drugs Market, by indication

6.5.2.Asia-Pacific Pain Management Drugs Market, by drug Class
6.5.3.Asia-Pacific Pain Management Drugs Market, by indication

6.6.LAMEA

6.6.1.Key market trends, growth factors, and opportunities
6.6.2.LAMEA Pain Management Drugs Market, by country

6.6.2.1.Brazil Pain Management Drugs Market, by drug class
6.6.2.2.Brazil Pain Management Drugs Market, by indication
6.6.2.3.Saudi Arabia Pain Management Drugs Market, by drug class
6.6.2.4.Saudi Arabia Pain Management Drugs Market, by indication
6.6.2.5.South Africa Pain Management Drugs Market, by drug class
6.6.2.6.South Africa Pain Management Drugs Market, by indication
6.6.2.7.Rest of LAMEA Pain Management Drugs Market, by drug class
6.6.2.8.Rest of LAMEA Pain Management Drugs Market, by indication

6.6.3.LAMEA Pain Management Drugs Market, by drug Class
6.6.4.LAMEA Pain Management Drugs Market, by indication

Chapter 7:COMPANY PROFILES

7.1.ABBOTT LABORATORIES

7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product portfolio
7.1.5.Business performance

7.2.ELI LILY AND COMPANY

7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Operating business segments
7.2.4.Product portfolio
7.2.5.Business performance
7.2.6.Key strategic moves and developments

7.3.ENDO HEALTH SOLUTIONS, INC. (ENDO INTERNATIONAL PLC.)

7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product portfolio
7.3.5.Business performance.

7.4.GLAXOSMITHKLINE PLC (GSK)

7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product portfolio
7.4.5.Business performance.
7.4.6.Key strategic moves and developments

7.5.JOHNSON & JOHNSON

7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.5.5.Business performance

7.6.MERCK & CO., INC.

7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance
7.6.6.Key strategic moves and developments

7.7.MYLAN N.V.

7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Operating business segments
7.7.4.Product portfolio
7.7.5.Business performance
7.7.6.Key strategic moves and developments

7.8.NOVARTIS INTERNATIONAL AG

7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Business performance
7.8.6.Key strategic moves and developments

7.9.PFIZER INC.

7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Business performance
7.9.6.Key strategic moves and developments

7.10.PURDUE PHARMA L.P.

7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Key strategic moves and developments



List of Figures



FIGURE 01.GLOBAL PAIN MANAGEMENT DRUGS MARKET SEGMENTATION
FIGURE 02.TOP WINNING STRATEGIES, 2017–2020
FIGURE 03.TOP WINNING STRATEGIES: NATURE AND TYPE, 2017–2020
FIGURE 04.TOP WINNING STRATEGIES: BY YEAR, 2017–2020
FIGURE 05.TOP PLAYER POSTIONING, 2019
FIGURE 06.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 07.MODERATE BARGAINING POWER OF BUYERS
FIGURE 08.MODERATE THREAT OF SUBSTITUTES
FIGURE 09.MODEARTE THREAT OF NEW ENTRANTS
FIGURE 10.MODERATE COMPETITIVE OF RIVALRY
FIGURE 11.DRIVER, RESTRAINSTS AND OPPORTUNITIES
FIGURE 12.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR NSAIDS BY COUNTRY, 2019 & 2027 (%)
FIGURE 13.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR ANESTHETIC BY COUNTRY, 2019 & 2027 (%)
FIGURE 14.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR ANTICONVULSANT BY COUNTRY, 2019 & 2027 (%)
FIGURE 15.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR ANTIMIGRAINE BY COUNTRY, 2019 & 2027 (%)
FIGURE 16.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR ANTIDEPRESSANT DRUGS BY COUNTRY, 2019 & 2027 (%)
FIGURE 17.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR OPIOIDS BY COUNTRY, 2019 & 2027 (%)
FIGURE 18.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR NON-NARCOTIC ANALGESICS BY COUNTRY, 2019 & 2027 (%)
FIGURE 19.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR ARTHMITIC PAIN BY COUNTRY, 2019 & 2027 (%)
FIGURE 20.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR NEUROPATHIC PAIN BY COUNTRY, 2019 & 2027 (%)
FIGURE 21.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR NEUROPATHIC PAIN BY COUNTRY, 2019 & 2027 (%)
FIGURE 22.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR CHRONIC PAIN BY COUNTRY, 2019 & 2027 (%)
FIGURE 23.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR POST-OPERATIVE PAIN BY COUNTRY, 2019 & 2027 (%)
FIGURE 24.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR MIGRAINEBY COUNTRY, 2019 & 2027 (%)
FIGURE 25.COMPARATIVE ANALYSIS OF PAIN MANAGEMENT DRUGS MARKET, FOR FIBROMYALGIA BY COUNTRY, 2019 & 2027 (%)
FIGURE 26.ABBOTT: NET SALES, 2017–2019 ($MILLION)
FIGURE 27.ABBOTT: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 28.ABBOTT: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 29.ELI LILLY: NET SALES, 2017–2019 ($MILLION)
FIGURE 30.ELI LILLY: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 31.ENDO: NET SALES, 2017–2019 ($MILLION)
FIGURE 32.ENDO: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 33.GSK: NET SALES, 2017–2019 ($MILLION)
FIGURE 34.GSK: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 35.GSK: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 36.J&J: NET SALES, 2017–2019 ($MILLION)
FIGURE 37.J&J: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 38.J&J: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 39.MERCK & CO., INC.: NET SALES, 2017–2019 ($MILLION)
FIGURE 40.MERCK & CO., INC.: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 41.MERCK & CO., INC.: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 42.MYLAN: NET SALES, 2017–2019 ($MILLION)
FIGURE 43.MYLAN: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 44.NOVARTIS: NET SALES, 2017–2019 ($MILLION)
FIGURE 45.NOVARTIS: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 46.NOVARTIS: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 47.PFIZER: NET SALES, 2017–2019 ($MILLION)
FIGURE 48.PFIZER: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 49.PFIZER: REVENUE SHARE, BY REGION, 2019 (%)


List of Tables



TABLE 01.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 02.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY NSAIDS, BY REGION, 2019–2027 ($MILLION)
TABLE 03.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY ANESTHETIC, BY REGION, 2019–2027 ($MILLION)
TABLE 04.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY ANTICONVULSANT, BY REGION, 2019–2027 ($MILLION)
TABLE 05.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY ANTIMIGRAINE DRUG, BY REGION, 2019–2027 ($MILLION)
TABLE 06.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY ANTIDEPRESSANT DRUGS, BY REGION, 2019–2027 ($MILLION)
TABLE 07.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY OPIOIDS, BY REGION, 2019–2027 ($MILLION)
TABLE 08.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY NON-NARCOTIC ANALGESICS, BY REGION, 2019–2027 ($MILLION)
TABLE 09.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 10.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY ARTHMITIC PAIN, BY REGION, 2019–2027 ($MILLION)
TABLE 11.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY NEUROPATHIC PAIN, BY REGION, 2019–2027 ($MILLION)
TABLE 12.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY CANCER PAIN, BY REGION, 2019–2027 ($MILLION)
TABLE 13.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY CHRONIC PAIN, BY REGION, 2019–2027 ($MILLION)
TABLE 14.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY POST-OPERATIVE PAIN, BY REGION, 2019–2027 ($MILLION)
TABLE 15.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY MIGRAINE, BY REGION, 2019–2027 ($MILLION)
TABLE 16.GLOBAL PAIN MANAGEMENT DRUGS MARKET, BY FIBROMYALGIA, BY REGION, 2019–2027 ($MILLION)
TABLE 17.GLOBAL PAIN MANAGEMENT DRUGS MARKET REVENUE, BY REGION, 2019–2027 ($MILLION)
TABLE 18.NORTH AMERICA PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 19.U.S. PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 20.U.S. PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2019–2027 ($MILLION)
TABLE 21.CANADA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 22.CANADA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 23.MEXICO PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 24.MEXICO PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 25.NORTH AMERICA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 26.NORTH AMERICA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 27.EUROPE PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 28.UK PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 29.UK PAIN MANAGEMENT DRUGS MARKET , BY INDICATION, 2019–2027 ($MILLION)
TABLE 30.GERMANY PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 31.GERMANY PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 32.FRANCE PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 33.FRANCE PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 34.ITALY PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 35.ITALY PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 36.SPAIN PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 37.SPAIN PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 38.REST OF EUROPE PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 39.REST OF EUROPE PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 40.EUROPE PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 41.EUROPE PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 42.ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 43.JAPAN PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 44.JAPAN PAIN MANAGEMENT DRUGS MARKET, BY INDICATIONS, 2019–2027 ($MILLION)
TABLE 45.CHINA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 46.CHINA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 47.AUSTRALIA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 48.AUSTRALIA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 49.INDIA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 50.INDIA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 51.SOUTH KOREA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 52.SOUTH KOREA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 53.TAIWAN PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 54.TAIWAN PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 55.REST OF ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 56.REST OF ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 57.ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 58.ASIA-PACIFIC PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 59.LAMEA PAIN MANAGEMENT DRUGS MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 60.BRAZIL PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 61.BRAZIL PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 62.SAUDI ARABIA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 63.SAUDI ARABIA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 64.SOUTH AFRICA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 65.SOUTH AFRICA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 66.REST OF LAMEA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 67.REST OF LAMEA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 68.LAMEA PAIN MANAGEMENT DRUGS MARKET, BY DRUG CLASS, 2019–2027 ($MILLION)
TABLE 69.LAMEA PAIN MANAGEMENT DRUGS MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 70.ABBOTT: COMPANY SNAPSHOT
TABLE 71.ABBOTT: OERATING SEGMENT
TABLE 72.ABBOTT: PRODUCT PORTFOLIO
TABLE 73.ELI LILLY: COMPANY SNAPSHOT
TABLE 74.LILLY: OPERATING SEGMENTS
TABLE 75.ELI LILLY: PRODUCT PORTFOLIO
TABLE 76.ELI LILLY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 77.ENDO: COMPANY SNAPSHOT
TABLE 78.ENDO: OPERATING BUSINESS SEGMENTS
TABLE 79.ENDO: PRODUCT PORTFOLIO
TABLE 80.GSK: COMPANY SNAPSHOT
TABLE 81.GSK: OPERATING SEGMENTS
TABLE 82.GSK: PRODUCT PORTFOLIO
TABLE 83.J&J: COMPANY SNAPSHOT
TABLE 84.J&J: OPERATING BUSINESS SEGMENTS
TABLE 85.J&J: PRODUCT PORTFOLIO
TABLE 86.MERCK & CO., INC.: COMPANY SNAPSHOT
TABLE 87.MERCK & CO., INC.: OPERATING SEGMENTS
TABLE 88.MERCK & CO., INC.: PRODUCT PORTFOLIO
TABLE 89.MERCK & CO., INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 90.MYLAN: COMPANY SNAPSHOT
TABLE 91.MYLAN: OPERATING BUSINESS SEGMENTS
TABLE 92.MYLAN: PRODUCT PORTFOLIO
TABLE 93.NOVARTIS: COMPANY SNAPSHOT
TABLE 94.NOVARTIS: OPERATING SEGMENTS
TABLE 95.NOVARTIS: PRODUCT PORTFOLIO
TABLE 96.PFIZER: COMPANY SNAPSHOT
TABLE 97.PFIZER: OERATING SEGMENT
TABLE 98.PFIZER: PRODUCT PORTFOLIO
TABLE 99.PURDUE: COMPANY SNAPSHOT
TABLE 100.PURDUE: PRODUCT PORTFOLIO